Antibacterial Nanoparticles Therapeutic (ANT) Study

The Defense Health Agency (DHA), through the Army Medical Research Acquisition Activity, is conducting market research for the Antibacterial Nanoparticles Therapeutic (ANT) Study. This research and development effort focuses on testing innovative antibacterial nanoparticles with phage-mimicking properties (PhANPs) against multi-drug resistant strains of *Pseudomonas aeruginosa*, a pathogen known for causing severe infections following battlefield injuries. The project involves a collaboration with the University of Notre Dame to utilize patented phage-mimicking technology to advance novel therapeutics toward Food and Drug Administration approval.

The scope of work requires the contractor to provide non-personal research and development services, including qualified personnel, laboratory facilities, and all necessary materials and supplies. This effort is categorized under NAICS 541713 Research and Development in Nanotechnology and PSC AN13 Health R&D Services; Health Care Services; Experimental Development. There is no assigned set-aside for this requirement.

The primary place of performance is Silver Spring, MD, and the response deadline for this sources sought notice is April 1, 2026. This notice, identified by solicitation number PANDHA-26-P-0000_036893, was published on March 18, 2026, and includes one attachment titled Request for Information PANDHA-26-P-0000 036893 ANT Study. Linda Hinson serves as the point of contact for this requirement.